Development of Parkinson's disease in patients with Narcolepsy.
Although amphetamine drugs can damage dopaminergic axons, it is unknown whether chronic treatment with amphetamine increases the risk of developing Parkinson's disease (PD). Of 1,152 consecutive PD patients, 3 had a prior diagnosis of narcolepsy. This rate is five times higher than expected (p = 0.02). These patients had typical onset of narcolepsy and underwent treatment with amphetamine. Although preliminary, this observation raises the possibility that some factors intrinsic to narcolepsy or its treatment may be a risk factor for PD.
Department of Neurology, University of California, San Francisco, 400 Parnassus Avenue, Box 0348, San Francisco, CA 94143, USA. Chad.Christine@ucsf.edu
Chadwick W
CW
Christine
William J
WJ
Marks
Jill L
JL
Ostrem
D000328:Adult; D017668:Age of Onset; D000978:Antiparkinson Agents / Q000627:therapeutic use; D002385:Cataplexy / Q000150:complications / Q000523:psychology; D000697:Central Nervous System Stimulants / Q000627:therapeutic use; D046690:Deep Brain Stimulation; D003913:Dextroamphetamine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D018476:Hypokinesia / Q000139:chemically induced; D007189:Indans / Q000627:therapeutic use; D038801:International Classification of Diseases; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009290:Narcolepsy / Q000150:complications* / Q000188:drug therapy; D018696:Neuroprotective Agents / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy / Q000209:etiology* / Q000628:therapy; D012890:Sleep / Q000502:physiology; D055815:Young Adult
D000978:Antiparkinson Agents; D000697:Central Nervous System Stimulants; D007189:Indans; D018696:Neuroprotective Agents; C031967:rasagiline; D007980:Levodopa; D003913:Dextroamphetamine